La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Kobayashi Pharmaceutical Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Kobayashi Pharmaceutical ha un patrimonio netto totale di ¥205.0B e un debito totale di ¥0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente ¥261.3B e ¥56.3B. L'EBIT di Kobayashi Pharmaceutical è ¥25.6B rendendo il suo rapporto di copertura degli interessi -34.4. Ha liquidità e investimenti a breve termine pari a ¥70.7B.

Informazioni chiave

Rapporto debito/patrimonio netto

JP¥0

Debito

Indice di copertura degli interessi	-31.7x
Contanti	JP¥60.36b
Patrimonio netto	JP¥209.73b
Totale passività	JP¥52.52b
Totale attività	JP¥262.25b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Kobayashi Pharmaceutical's (TSE:4967) Soft Earnings Are Actually Better Than They Appear

Aug 21

Getting In Cheap On Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) Is Unlikely

Aug 04

Investor Optimism Abounds Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) But Growth Is Lacking

Apr 21

Estimating The Fair Value Of Kobayashi Pharmaceutical Co., Ltd. (TSE:4967)

Apr 03

Investors Met With Slowing Returns on Capital At Kobayashi Pharmaceutical (TSE:4967)

Feb 27

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( ¥138.4B ) di 4967 superano le sue passività a breve termine ( ¥51.0B ).

Passività a lungo termine: Le attività a breve termine di 4967 ( ¥138.4B ) superano le sue passività a lungo termine ( ¥5.3B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 4967 è esente da debiti.

Riduzione del debito: 4967 non ha debiti rispetto a 5 anni fa, quando il suo rapporto debito/patrimonio netto era 0.3%.

Copertura del debito: 4967 non ha debiti, pertanto non deve essere coperto dal flusso di cassa operativo.

Copertura degli interessi: 4967 non ha debiti, pertanto la copertura dei pagamenti degli interessi non è un problema.

Kobayashi Pharmaceutical Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Kobayashi Pharmaceutical's (TSE:4967) Soft Earnings Are Actually Better Than They Appear

Consensus EPS estimates fall by 22%

Getting In Cheap On Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) Is Unlikely

Kobayashi Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Aug 08, 2024

Upcoming dividend of JP¥44.00 per share

Consensus EPS estimates fall by 12%

Price target decreased by 8.0% to JP¥6,348

First quarter 2024 earnings: EPS misses analyst expectations

Price target decreased by 16% to JP¥6,898

Kobayashi Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on May 10, 2024

Investor Optimism Abounds Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) But Growth Is Lacking

New minor risk - Share price stability

Estimating The Fair Value Of Kobayashi Pharmaceutical Co., Ltd. (TSE:4967)

Investor sentiment deteriorates as stock falls 18%

Investors Met With Slowing Returns on Capital At Kobayashi Pharmaceutical (TSE:4967)

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2024

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Kobayashi Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Feb 09, 2024

Upcoming dividend of JP¥53.00 per share at 1.5% yield

New minor risk - Shareholder dilution

Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) announces an Equity Buyback for 1,924,600 shares, representing 2.53% for ¥11,999.88 million.

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) acquired Focus Consumer Healthcare, LLC.

Second quarter 2023 earnings: EPS exceeds analyst expectations

Upcoming dividend of JP¥39.00 per share at 1.1% yield

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 30, 2023

Upcoming dividend of JP¥47.00 per share

Kobayashi Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on May 10, 2023

Third quarter 2022 earnings: EPS exceeds analyst expectations

Third quarter 2022 earnings: EPS exceeds analyst expectations

Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) announces an Equity Buyback for 1,265,800 shares, representing 1.64% for ¥9,999.82 million.

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of JP¥38.00 per share

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Upcoming dividend of JP¥44.00 per share

Third quarter 2021 earnings released: EPS JP¥89.58 (vs JP¥90.07 in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥54.41 (vs JP¥57.27 in 2Q 2020)

Upcoming dividend of JP¥35.00 per share

First quarter 2021 earnings released: EPS JP¥46.42 (vs JP¥47.87 in 1Q 2020)

Full year 2020 earnings released: EPS JP¥246 (vs JP¥244 in FY 2019)

Kobayashi Pharmaceutical Co., Ltd. to Report Q1, 2021 Results on Apr 27, 2021

New 90-day low: JP¥10,460

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2021

Full year 2020 earnings released: EPS JP¥246 (vs JP¥244 in FY 2019)

Revenue and earnings miss expectations

Kobayashi Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Feb 01, 2021

New 90-day high: JP¥12,880

Upcoming Dividend of JP¥41.00 Per Share

New 90-day high: JP¥12,610

Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) signed an contract to acquire Alva-Amco Pharmacal Companies, Inc. from Trusts all owned by the founder's family for approximately $110 million.

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane